Implement an Effective Change Management System throughout GMP and Validation Environments. Eileen Cortes February 23, 2017

Size: px
Start display at page:

Download "Implement an Effective Change Management System throughout GMP and Validation Environments. Eileen Cortes February 23, 2017"

Transcription

1 Implement an Effective Change Management System throughout GMP and Validation Environments Eileen Cortes February 23, 2017

2 Agenda Change Management Principles Change Management Process and Change Control Change Management Process Atypical Change Management Process Flow Case Study Open Discussion

3 Change Management Principles It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change

4 Why We Need Change Management? Because we DO! What is change management? Per ICH Q10 Innovation, continuous improvement, outputs of process performance, product quality monitoring and CAPA drive change. To evaluate, approve, and implement these changes properly an effective change management process must be in place Ensures continual improvement is undertaken in a timely and effective manner. Provides a high degree of assurance there are no unintended consequences of the change. Change Management is a more broad concept that change control. Change Management includes the oversight of how we drive changes in our sites and how the change process is implemented. Not only Change Management has direct impact in our processes effectiveness but also in our financial outcome. Regulations enforce them, Change Management applies to the whole product lifecycle per ICH Q10.

5 Change Management through Lifecycle Stages Quality Risk Management shall be applied to evaluate changes Proposed changes shall be evaluated against the complete product lifecycle: Design / System Engineering Product Development / Portfolio Manufacturing / Data Management Regulatory Marketing Patient / Sales

6 Application of Change Management through Lifecycle

7 Regulations and Change Management ICH Q10 Change Management: A systematic approach to proposing, evaluating, approving, implementing, and reviewing changes. (ICH Q10) FDA Change control: is another well-known CGMP concept that focuses on managing change to prevent unintended consequences. The CGMP regulations provide for change control primarily through the assigned responsibilities of the quality control unit. Certain major manufacturing changes (e.g., changes that alter specifications, a critical product attribute or bioavailability) require regulatory filings and prior regulatory approval (21 CFR , 514.8, and ) Change control: with regard to pharmaceuticals is addressed in more detail in the CGMP regulations. A firm may want to revisit the adequacy of the design of the manufacturing facility ( ), the design of the manufacturing equipment ( ), the design of the production and control procedures ( ), or the design of laboratory controls ( )

8 Regulations and Change Management ISO 9001:2015 Focus on Quality Management Evaluation / Risk Assessment Implementation Integrity Resources Planning and Control Communication

9 Regulations and Change Management ICH Q8 Pharmaceutical Development ICH Q9 Quality Risk Management ICH Q10 Quality Systems Knowledge understanding - the use of quality risk management principles, supported by the implementation of ICH Q8, ICH Q9 and ICH Q10 principles provides the opportunity to be Science based and execute risk based post-approval changes Drive innovation and Continuous improvement ICH Q10

10 Change Management Cycle Risk Assessment Monitor / Continuous Verification Knowledge Collect Data & Evaluate Variation Implement Change

11 Change Management vs. Change Control The scope of change management is much broader than change control, which was typically applied to one change at a time Change management includes the oversight and management of the entire portfolio of changes and the change process, including all the components of change control

12 Change Management Process and Change Control

13 Roles and Responsibilities Roles and Responsibilities must be clearly defined. Per ICH Q10 Proposed changes should be evaluated by expert teams contributing the appropriate expertise and knowledge from relevant areas (e.g., Pharmaceutical Development, Manufacturing, Quality, Regulatory Affairs, and Medical) to ensure the change is technically justified Minimum Roles Originator Change Owner Change Subject Matter Expert (SME) Regulatory Affairs Functional Areas Quality Assurance

14 Change Management Main Components Change Proposal Regulatory Assessment Impact Assessment Implementation Plan Change Evaluation Implementation Process Closure Effectiveness Check

15 Change Proposal Develop Change Proposal Description of Change Includes a detailed description of the proposed change including the current state (pre- change) and the future state (post-change) with a summary of planned outcome (as left operating state of control). Define change boundaries, which is what is in scope of change. A gap assessment of current vs. proposed may be used to highlight change points when current state of change is being revised/optimized and aid with construction of risk identification. Justification of Change: Provides the circumstances that prompted the change proposal, giving rationale and expected benefit of the proposed change and assessment of past released lots to ensure equivalency of lots released.

16 Regulatory Assessment Regulatory Affairs will determine impact on: Regulatory Risks Regulatory Licensing Policies Regulatory Submissions Product Labeling

17 Risk / Impact Assessment Risk Assessment must be performed to assess potential impact of change. The facility in which will accommodate the change should be considered under a facility assessment that assesses the change relative to the capability of the classified facility to uphold product safety, identity, strength and/or quality that is at least comparable to the state prior to change or intended state. Changes to specifications, sample plans test methods, product controls, reference standards, standard curve standards, etc. should be assessed for comparability to state prior to change and equivalency risks should be identified. Changes initiated at contract manufacturing organizations, contract laboratory or suppliers should be assessed for comparability to state prior to change and equivalency risks should be identified. Assessors are to assess impact to Documentation, Trainings, Validation, Equipment/Systems, Product, Product License/Dossier, Product Hold Times, Stability, GMP Processes or Computerized Systems (Functionality, Security, Integration and Interfaces)

18 Implementation Plan & Target Dates The Implementation Plan Key Areas are: Target Implementation Date Date that Change will be employed. Be realistic! Implementation Plan The implementation plan should list all steps required to implement change Contingency Plan Rollback plan, as applicable

19 Change Evaluation and Approval for Implementation The Change Owner employs implementation tasks according to approved plan. The Change Owner ensures completion of the implementation actions outlined in the parent record by the implementation due date and begins routing for approval. If target implementation date cannot be met, owner is to request an extension and provide justification. The Quality task approver ensures completion of the assigned tasks by the date due. The Change Owner confirms required data, evidence of performance of the implementation plan (QC data summary, validation summary report, work orders, etc.) are attached to the change record, as necessary.

20 Implementation Process Implementation Process minimum checks: The Owner and/or Task Owners employ implementation tasks according to approved plan. The Owner ensures completion of the implementation actions outlined in the record by the implementation due date and begins routing for approval. If target implementation date cannot be met, owner is to request an extension and provide justification. The Quality approver ensures completion of the assigned tasks by the date due. The Owner confirms required data, evidence of performance of the implementation plan (QC data summary, validation summary report, work orders, etc.) are attached to the record, as necessary.

21 Closure Summary Summary, results and deliverables of the changes that are implemented as part of the implementation plan Identify whether the change is executed to plan. If No, provide justification Route The owner routes the change record for closure to department Approvers who are manager level and above and Quality with all supporting documentation by target implementation due date Approvals The record approvers and Quality ensures that the Change Completion is approved within XXX calendar days of the completion of the implementation plan (XXX: recommended - 30 days)

22 Effectiveness Check What is an Effectiveness Check? Predetermined criteria to assess the effectiveness of the change Ensures there are no other unforeseen consequences on other classified areas or state of control (which might not have been apparent with change proposal approval) Owner Opens the Effectiveness check record, identifies acceptance criteria and targets completion date Quality Quality approver reviews the Effectiveness Check Summary to confirm satisfactory completion of the Effectiveness Check by ensuring all acceptance criteria are met and the adequate objective evidence is referenced and attached

23 Change Management Process Atypical

24 Emergency Changes What is an Emergency Change? A change implemented, without prior assessment by the change review team or SMEs in response to a failure. The change restores operation where failure to do so would have posed a likely or imminent adverse impact to product quality, operator safety, data integrity or equipment. Deviation should be linked to the record. All emergency changes require at a minimum: Approval from respective functional area management Quality and can be implemented once verbal approval has been received Change Owner initiates change record within 24 hours of emergency change Change proposal must be completed and submitted to change review team within X business days (X days recommended, 5 business days)

25 Amendments If a change to the approved implementation plan is needed owner will initiate an amendment and document: A proposed due date (new target implementation date), as applicable to accommodate new record scope Description of the proposed change Description of activities performed to date Justification for amendment Attachments supporting amendment, if applicable Approvers as designated functional area management and Quality

26 Case Study

27 Q&A Open Discussion

28 Thank You!

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017 CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection

More information

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017 Strategies to Revise Quality Policy and Quality Objectives Eileen Cortes February 22, 2017 Agenda Elements of Compliance Quality Policy Outline Quality Strategy and Objectives Case Study Open Discussion

More information

Develop a Roadmap for the Implementation of a Global CSV Program. Eileen Cortes April 26, 2017

Develop a Roadmap for the Implementation of a Global CSV Program. Eileen Cortes April 26, 2017 Develop a Roadmap for the Implementation of a Global CSV Program Eileen Cortes April 26, 2017 Agenda CSV Regulation Principles CSV Lifecycle Approach CSV and Quality Management Governance Program and CSV

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

Enabling Improvement through the Product Lifecycle: Change Management within a PQS

Enabling Improvement through the Product Lifecycle: Change Management within a PQS Enabling Improvement through the Product Lifecycle: Change Management within a PQS Denise DiGiulio, Senior Advisor OPQ Office of Process and Facilities PDA Chapter Meeting Melbourne, Australia April 3,

More information

Q10 PHARMACEUTICAL QUALITY SYSTEM

Q10 PHARMACEUTICAL QUALITY SYSTEM Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights

More information

Overview of Amgen s CQP Commissioning and Qualification Program Steve Wisniewski Principal Compliance Consultant, CAI Past Chairman ISPE C&Q COP

Overview of Amgen s CQP Commissioning and Qualification Program Steve Wisniewski Principal Compliance Consultant, CAI Past Chairman ISPE C&Q COP May 1-3, 2012 Javits Center New York, NY Introduction to ISPE GUIDE: SCIENCE AND RISK-BASED APPROACH FOR THE DELIVERY OF FACILITIES, SYSTEMS, AND EQUIPMENT & Overview of Amgen s CQP Commissioning and Qualification

More information

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11. References Concept Principle a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which

More information

While the recognition

While the recognition Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change

More information

Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED

Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Presented by Raymond A. Bonner Nathan C. Sheers SIDLEY AUSTIN BROWN & WOOD, LLP Washington, D.C. (202) 736-8000 To The Fourth Annual Pharmaceutical

More information

EU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011

EU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011 Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill

More information

Manual 069 The validation of facilities and system

Manual 069 The validation of facilities and system 1. Purpose The purpose of this guideline is to provide requirements for the Validation of Facilities and Systems and to outline recommendations on how to achieve compliance. 2. Scope This guideline can

More information

Design Quality. Indu Lakshman

Design Quality. Indu Lakshman Design Quality Indu Lakshman Overview New product development (NPD) covers the complete process of bringing a new product to market. In commercial terms, new product development is described in the literature

More information

San Jose, California, USA

San Jose, California, USA Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations DRAFT GUIDANCE This draft guidance document is being distributed for comment purposes only.

More information

Risk Based Validation. Why, How and with what tools?

Risk Based Validation. Why, How and with what tools? Risk Based Validation Why, How and with what tools? Tech Talk Agenda History of FDA GMP initiative for the 21 st Century. Industry response to FDA initiative. Harmonisation through ICH. ASTM Standard on

More information

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents

More information

Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan

Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification

More information

Lifecycle Product Quality Risk Management

Lifecycle Product Quality Risk Management Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,

More information

EU Annex 11 US FDA , (g), (i), 11 Orlando López 09-APR

EU Annex 11 US FDA , (g), (i), 11 Orlando López 09-APR Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill

More information

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active

More information

ICH Quality Implementation Working Group POINTS TO CONSIDER

ICH Quality Implementation Working Group POINTS TO CONSIDER ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements

More information

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions) 21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software

More information

Strategies for Risk Based Validation of Laboratory Systems

Strategies for Risk Based Validation of Laboratory Systems Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,

More information

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852 22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:

More information

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern

More information

Pharmaceutical cgmps for the 21st Century February 2004

Pharmaceutical cgmps for the 21st Century February 2004 Pharmaceutical cgmps for the 21st Century February 2004 Ludwig Huber Compliance Fellow for Life Sciences and Chemical Analysis Chairperson: Rob Sample FDA GxP Regulations Along the Drug Life Basic Research

More information

Challenges in Implementing Knowledge Management within ICH Q10

Challenges in Implementing Knowledge Management within ICH Q10 Challenges in Implementing Knowledge Management within ICH Q10 SYMPOSIUM - New Frontiers in Manufacturing Technology, Regulatory - Brasilia Joseph C. Famulare Vice President, Global Head Compliance and

More information

Risk-based Approach to Part 11 and GxP Compliance

Risk-based Approach to Part 11 and GxP Compliance Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!

More information

Good Distribution Practices Toolkit Change Control 10 March 2016

Good Distribution Practices Toolkit Change Control 10 March 2016 Good Distribution Practices Toolkit Change Control 10 March 2016 1 Disclaimer The content of this presentation were derived mainly from WHO training material on Change Control and edited to suit the Distributor

More information

Stage 3 - Process Validation: Measuring what matters

Stage 3 - Process Validation: Measuring what matters Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company

More information

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND

More information

Post-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool

Post-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool Post-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool Dr. Markus Goese Lead EU CMC Regulatory Policy F. Hoffmann-La Roche Ltd, Basel - Switzerland Presentation

More information

FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy

FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy CBI Statistics in Validation FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy Jerry Lanese Ph.D. The Lanese Group, Inc. 2017 The Lanese

More information

Pharmaceutical quality requirements

Pharmaceutical quality requirements Pharmaceutical quality requirements through development to commercial medicinal product December 4, 2014 Karin Walhagen Biomedicine the Profession Biomedicine Master Program at Lund University Patient

More information

ICH Q8/Q8(R)

ICH Q8/Q8(R) Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since

More information

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!

More information

Oursourcing and Supplier Qualification from the perspective of the pharmaceutical Industry

Oursourcing and Supplier Qualification from the perspective of the pharmaceutical Industry Oursourcing and Supplier Qualification from the perspective of the pharmaceutical Industry 1 Presentation Outline Pharmaceutical Quality Management Partner Selection and Qualification Shipping Qualification

More information

Guidance for Industry and FDA:

Guidance for Industry and FDA: 1227 25th St., NW Washington, DC 20037-1156 Guidance for Industry and FDA: Application of cgmp Regulations to Combination Products: Frequently Asked Questions PROPOSED GUIDANCE January 15, 2007 This guidance

More information

Combination Products: QS & Design Controls Requirements

Combination Products: QS & Design Controls Requirements Combination Products: QS & Design Controls Requirements M. Isabel Tejero, MD PhD Office of Compliance CDRH, FDA Isabel.Tejero@fda.hhs.gov Presentation Goals Introduction to combination product CGMP requirements

More information

THE COMPLETE GUIDE TO FDA-REGULATED SUPPLIER QUALIFICATION & QUALITY MANAGEMENT

THE COMPLETE GUIDE TO FDA-REGULATED SUPPLIER QUALIFICATION & QUALITY MANAGEMENT THE COMPLETE GUIDE TO FDA-REGULATED SUPPLIER QUALIFICATION & QUALITY MANAGEMENT A risk-based approach to qualifying, managing and auditing third party providers TABLE OF CONTENTS 1 Outsourcing under greater

More information

Validation Best Practices Jeb Bullis Senior Account Executive

Validation Best Practices Jeb Bullis Senior Account Executive Validation Best Practices Jeb Bullis Senior Account Executive Today s Topics Introduction Key Terms Regulatory Requirements Validation Overview Best Practice Responses to Frequently Asked Questions Validating

More information

Developing an Internal Quality Auditing Program

Developing an Internal Quality Auditing Program Developing an Internal Quality Auditing Program SeerPharma Pty Lt Capsig August 2009 1 Critical Success Factors Culture of Compliance Integrate quality systems and risk management principles Well defined

More information

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June

More information

Introduction and Case Sharing of FDA CGMP Inspections

Introduction and Case Sharing of FDA CGMP Inspections Presentation title Date Introduction and Case Sharing of FDA CGMP Inspections Second Russian GMP Conference 2017 Andrew Chang, Ph.D Vice President, Quality and Regulatory Compliance Novo Nordisk A/S Presentation

More information

The Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management

The Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions

More information

Regulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)

Regulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0) Regulatory Overview Annex 11 and Part 11 Sion Wyn Conformity +[44] (0) 1492 642622 sion.wyn@conform-it.com 1 Two Key Regulations Annex 11 21 CFR Part 11 Apply to the regulated company, but often have a

More information

Cell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.

Cell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying

More information

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit. FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis

More information

Regulation of Active Pharmaceutical Ingredients (API)

Regulation of Active Pharmaceutical Ingredients (API) Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations

More information

Pharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit

Pharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing

More information

OPERATIONS MANUAL ISO 9001 Quality Management System

OPERATIONS MANUAL ISO 9001 Quality Management System OPERATIONS MANUAL * ISO 9001 Quality Management System Page: 1 of 19 Revision History Date Change Notice Change Description 5/30/2012 Original Original Release. 9/20/2012 005 Clarify post-delivery exclusion

More information

Inspection. Implementation of ICH Q8, Q9, Q10

Inspection. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory

More information

GMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd

GMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd GMP Compliance George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd June 2017 Overview GMP Definition and Regulation Our Philosophy and Strategy for Compliance Project Lifecycle Deliverables Master

More information

The ABCs and Challenges of GMP The American Experience

The ABCs and Challenges of GMP The American Experience The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine

More information

Impact of the IVD Regulations. Barbara Fallowfield Managing Director

Impact of the IVD Regulations. Barbara Fallowfield Managing Director Impact of the IVD Regulations Barbara Fallowfield Managing Director What will I cover today? Timelines Key Changes Classification Clinical Evidence Requirements Third Parties Vigilance and Post Marketing

More information

Change Control Overview

Change Control Overview Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change

More information

Journal home page: RESEARCH ARTICLE

Journal home page:  RESEARCH ARTICLE Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;

More information

AIMCAL R2R Conference 11/15/2018 1

AIMCAL R2R Conference 11/15/2018 1 Coating Line Operations for the Production of Drug-Containing Transdermal Patches Presented by: Ken Glade Director of Engineering LTS Lohmann Therapy Systems Kenneth.glade@lts-corp.com +1 (973) 396-5384

More information

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing

More information

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Guidelines for Process Validation of Pharmaceutical Dosage Forms Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical

More information

Synopsis: FDA Process Validation Guidance

Synopsis: FDA Process Validation Guidance Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.

More information

GMP Challenges to Global Pharma Companies

GMP Challenges to Global Pharma Companies GMP Challenges to Global Pharma Companies Muralidhara B. Gavini, Ph.D. Senior Assistant Country Director India Mumbai Office, Office of International Programs Office of the Commissioner Food & Drug Administration

More information

Quality System Regulation (QSR) Training

Quality System Regulation (QSR) Training Quality System Regulation (QSR) Training Or How to Ensure Development, Production and Sale of Safe, Effective, Consistent Product FDLI February 2003 Overview QSR History, Purpose and Scope Changes from

More information

Prevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper

Prevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper Prevent Quality System Deficiencies by Conducting Effective Internal Audits Whitepaper An internal audit system is one of the most effective ways to monitor, analyze, control, and improve quality management

More information

QUALITY AGREEMENT. The following Agreement has been concluded between

QUALITY AGREEMENT. The following Agreement has been concluded between QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter

More information

Testing 2. Testing: Agenda. for Systems Validation. Testing for Systems Validation CONCEPT HEIDELBERG

Testing 2. Testing: Agenda. for Systems Validation. Testing for Systems Validation CONCEPT HEIDELBERG CONCEPT HEIDELBERG GMP Compliance for January 16-17, 2003 at Istanbul, Turkey Testing for Systems Validation Dr.-Ing. Guenter Generlich guenter@generlich.de Testing 1 Testing: Agenda Techniques Principles

More information

Demystify Governance, Risk & Compliance For Lifesciences

Demystify Governance, Risk & Compliance For Lifesciences www.hcltech.com Demystify Governance, Risk & Compliance For Lifesciences Competitive global markets, more-demanding patients, regulations from multiple regulatory authorities and high product development

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT

EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago

More information

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017 DATA INTEGRITY & CSV:

More information

Harmonizing Manufacturing across Multiple Sites and Regions

Harmonizing Manufacturing across Multiple Sites and Regions Harmonizing Manufacturing across Multiple Sites and Regions ISCT North America Regional Meeting Philadelphia, Pennsylvania Byron T. McAllister B.T. McALLISTER ASSOCIATES, INC. Tuesday, 10 September 2013

More information

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 7 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2013 Inspections, Compliance, Enforcement, and Criminal Investigations

More information

Validation An International Perspective

Validation An International Perspective Validation An International Perspective Agenda Perceived industry problems - From QTPP/PQA Process Validation Paradigm shifts Process Validation based on QbD, Design Space, etc. Incremental changes Plain

More information

AAMI Quality Systems White Paper

AAMI Quality Systems White Paper AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,

More information

PMDA Perspective: Regulatory Updates on Process Validation Standard

PMDA Perspective: Regulatory Updates on Process Validation Standard CMC Strategy Forum Japan 2014 Tokyo, Japan, December 8-9, 2014 PMDA Perspective: Regulatory Updates on Validation Standard Kazunobu Oyama, PhD Office of Cellular and Tissue-based Products PMDA, Japan Disclaimer:

More information

Interpharm Praha A.S. 10/18/16

Interpharm Praha A.S. 10/18/16 Interpharm Praha A.S. 10/18/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Return Receipt Requested

More information

Audit Program Background Definition Management Example Content Risk assessment approach

Audit Program Background Definition Management Example Content Risk assessment approach AUDIT PROGRAM Audit Program Background Definition Management Example Content System audits vs study audits Risk assessment approach ICH-GCP E6 new content Management Example 2 Background - Definition There

More information

Current version 13 October 2016

Current version 13 October 2016 Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order

More information

Global Regulatory Affairs

Global Regulatory Affairs Navigating the Regulatory Landscape for Combination Products Presented by: Becky Leibowitz, Ph.D. Associate Director, RA-CMC, Medical Devices & Combination Products Janssen Research & Development, LLC

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:

More information

R&D of Biological Products. Rochapon Wacharotayankun, Ph.D., R.Ph.

R&D of Biological Products. Rochapon Wacharotayankun, Ph.D., R.Ph. R&D of Biological Products Rochapon Wacharotayankun, Ph.D., R.Ph. Topic Biological products research and development Process development Product development Novel antigens and Novel excipients Quality

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline

More information

SYSTEMKARAN ADVISER & INFORMATION CENTER QUALITY MANAGEMENT SYSTEM ISO9001:

SYSTEMKARAN ADVISER & INFORMATION CENTER QUALITY MANAGEMENT SYSTEM ISO9001: SYSTEM KARAN ADVISER & INFORMATION CENTER QUALITY MANAGEMENT SYSTEM ISO9001:2015 WWW.SYSTEMKARAN.ORG 1 WWW.SYSTEMKARAN.ORG Foreword... 5 Introduction... 6 0.1 General... 6 0.2 Quality management principles...

More information

Q8 Pharmaceutical Development

Q8 Pharmaceutical Development Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,

More information

Process Validation (PV): Designing an Effective PV Program. Mike Porter Compliance Consultant Commissioning Agents Inc.

Process Validation (PV): Designing an Effective PV Program. Mike Porter Compliance Consultant Commissioning Agents Inc. Process Validation (PV): Designing an Effective PV Program Mike Porter Compliance Consultant Commissioning Agents Inc. (CAI) 24Apr2013 Agenda Process Validation Background Stage 1: Process Design Stage

More information

Addressing Key FDA Citations with Training. Align UL EduNeering Courses to Top FDA Warning Letter Topics

Addressing Key FDA Citations with Training. Align UL EduNeering Courses to Top FDA Warning Letter Topics Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter Topics Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter

More information

An Industry Perspective

An Industry Perspective Controls An Industry Perspective Presented by: Jay Gerondale Amgen Inc. Overview Why are We Here? What are Controls? Control Elements Product Development Steps Conclusion Bridging Making a Combination

More information

Update on the Regulatory Considerations of Pharmaceutical Product Lifecycle Management (ICH Q12) from a Health Authority Perspective

Update on the Regulatory Considerations of Pharmaceutical Product Lifecycle Management (ICH Q12) from a Health Authority Perspective Update on the Regulatory Considerations of Pharmaceutical Product Lifecycle Management (ICH Q12) from a Health Authority Perspective Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality

More information

Combination Products Part 4 Compliance and Implementation at multi-site Network

Combination Products Part 4 Compliance and Implementation at multi-site Network Combination Products Part 4 Compliance and Implementation at multi-site Network Vijay Damodaran Eli Lilly & Company September 27, 2017 Contents Key cgmp requirements for combination products How to perform

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, 6 February 2014 SANCO/TSE/ The received contributions together with the identity of

More information

Notice. Health Canada is pleased to announce the adoption of the ICH guidance Q8, Q9 and Q10 Questions & Answers (R4).

Notice. Health Canada is pleased to announce the adoption of the ICH guidance Q8, Q9 and Q10 Questions & Answers (R4). February 5, 2016 Notice Our file number: 16-100246-83 Adoption of International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance:

More information

Pharmaceutical Quality System (PQS)

Pharmaceutical Quality System (PQS) Implementation of ICH Q8, Q9, Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Structure of

More information

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

UNCONTROLLED DOCUMENT WHEN PRINTED

UNCONTROLLED DOCUMENT WHEN PRINTED 1. PURPOSE 1.1. The purpose of this procedure is to provide for a system and instructions, and to assign responsibilities for receiving, processing, and investigating customer complaints. 2. APPLICATION

More information